Finance

Lists
Why is SRPT down ၅.၃၃%?
Dive Deeper
SRPT:NASDAQ
Sarepta Therapeutics Inc
၁၆.၅၁ US$
-၅.၃၃%
(-၀.၉၃) 1D
၁၆.၇၅ US$
+၁.၄၅% (+၀.၂၄)
After hours
Closed: အောက် ၁၃, GMT-၄ ၁၆:၀၀:၀၀  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SRPT...
Open
၁၇.၁၂ US$
High
၁၇.၂၃ US$
Low
၁၆.၄၁ US$
Mkt. cap
၁၇၄.၃၉ ဋေ
Avg. vol.
၂.၉၂ သန်း
Volume
၃.၆၉ သန်း
52-wk high
၂၄.၆၈ US$
52-wk low
၁၄.၆၉ US$
EPS
-၁.၆၆ US$
Beta
၀.၃၈
Shares outstanding
၁၀.၅၆ ကုဋေ
No. of employees
၈၃၅
Open
၁၇.၁၂ US$
High
၁၇.၂၃ US$
Low
၁၆.၄၁ US$
Mkt. cap
၁၇၄.၃၉ ဋေ
Avg. vol.
၂.၉၂ သန်း
Volume
၃.၆၉ သန်း
52-wk high
၂၄.၆၈ US$
52-wk low
၁၄.၆၉ US$
EPS
-၁.၆၆ US$
Beta
၀.၃၈
Shares outstanding
၁၀.၅၆ ကုဋေ
No. of employees
၈၃၅
News stories
From web sources and news partners
BigGo Finance
BigGo Finance
·
ပြီးခဲ့သည့် ၃၂ မိနစ်
NY Stocks Fall as Dow Drops 180 Points; Crude Rises $1.10 on Middle East Concerns
Investor's Business Daily
Investor's Business Daily
·
ပြီးခဲ့သည့် ၄၂ မိနစ်
Dow Jones Futures: Stock Market Holds Up As Meta, AMD Lead Buys; ASML, CPI Inflation Due
Profile
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs. Wikipedia
About Sarepta Therapeutics Inc
CEODouglas S. Ingram
Employees၈၃၅
Founded၁၉၈၀
Headquarters-
Sector-
Analyst ratings
Based on 16 analysts giving stock ratings to SRPT in the past 3 months
Hold
Buy
3
Hold
9
Sell
4
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for SRPT in the last 3 months.
Highest
Current ၁၆.၅၁ US$
၃၈.၀၀ US$ (+၁၃၀.၁၆%)
Average
၂၁.၆၄ US$ (+၃၁.၀၇%)
Lowest
၅.၀၀ US$ (-၆၉.၇၂%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tazeen Ahmad
Bank of America Securities
Sell
Reiterated
၁၈.၀၀ US$
+၉%
10/09/2026
Brian Abrahams
RBC Capital
Hold
Maintained
၁၇.၀၀ US$
+၃%
10/09/2026
Mitchell Kapoor
H.C. Wainwright
Sell
Reiterated
၅.၀၀ US$
-၆၉.၇%
10/05/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
၃၈.၀၀ US$
+၁၃၀.၂%
10/02/2026
Yun Zhong
Wedbush
Buy
Maintained
၃၅.၀၀ US$
+၁၁၂%
09/30/2026
Anupam Rama
J.P. Morgan
Hold
Reiterated
၂၀.၀၀ US$
+၂၁.၁%
09/30/2026
Lachlan Hanbury Brown
William Blair
Hold
Reiterated
-
-
09/28/2026
Gil Blum
Needham
Sell
Maintained
-
-
09/28/2026
Yigal Nochomovitz
Citi
Sell
Maintained
၁၃.၀၀ US$
-၂၁.၃%
09/27/2026
Gavin Clark-Gartner
Evercore ISI
Hold
Maintained
၁၉.၀၀ US$
+၁၅.၁%
08/10/2026
Eliana Merle
Barclays
Hold
Maintained
၂၀.၀၀ US$
+၂၁.၁%
08/07/2026
Kristen Kluska
Cantor Fitzgerald
Hold
Maintained
၂၁.၀၀ US$
+၂၇.၂%
08/05/2026
Kostas Biliouris
Oppenheimer
Buy
Maintained
၃၅.၀၀ US$
+၁၁၂%
08/06/2026
Michael Ulz
Morgan Stanley
Hold
Reiterated
၂၅.၀၀ US$
+၅၁.၄%
08/06/2026
Biren Amin
Piper Sandler
Hold
Maintained
၂၀.၀၀ US$
+၂၁.၁%
08/06/2026
Ritu Baral
TD Cowen
Hold
Reiterated
၁၇.၀၀ US$
+၃%
08/06/2026
Uy Ear
Mizuho Securities
Buy
Maintained
၃၁.၀၀ US$
+၈၇.၈%
07/10/2026
Andy Chen
Wolfe Research
Buy
Upgraded
၂၇.၀၀ US$
+၆၃.၅%
07/08/2026
Stephen Brozak
WBB Securities
Buy
Maintained
၃၈.၀၀ US$
+၁၃၀.၂%
03/26/2026
Unknown Analyst
WBB Securities
Buy
Maintained
၃၈.၀၀ US$
+၁၃၀.၂%
03/26/2026
David Hoang
Deutsche Bank
Sell
Maintained
၁၄.၀၀ US$
-၁၅.၂%
03/26/2026
William Pickering
Bernstein
Hold
Maintained
၂၀.၀၀ US$
+၂၁.၁%
03/25/2026
Joseph Schwartz
Leerink Partners
Hold
Maintained
၁၅.၀၀ US$
-၉.၁%
03/25/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
၁၉.၀၀ US$
+၁၅.၁%
03/09/2026
Brian Skorney
Robert W. Baird
Hold
Maintained
၂၀.၀၀ US$
+၂၁.၁%
02/26/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
၁၇.၀၀ US$
+၃%
02/25/2026
Sami Corwin
William Blair
Hold
Reiterated
-
-
02/26/2026
Last report
၂၀၂၆ ဩ ၅
Fiscal period
Q2 2026
၀.၆၄ US$ / ၀.၄၉ US$
+၃၁.၆၇%beat
Revenue / Est. (USD)
၄၀.၁၃ ကုဋေ / ၃၆.၉၆ ကုဋေ
+၈.၅၆%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၃၉.၉၄ ကုဋေ
၄၄.၂၉ ကုဋေ
၇၃.၀၈ ကုဋေ
၄၀.၁၃ ကုဋေ
Cost of goods sold
၃၆.၉၇ ကုဋေ
၇၂.၄၀ ကုဋေ
၂၆.၂၇ ကုဋေ
၂၄.၀၆ ကုဋေ
Cost of revenue
၃၆.၉၇ ကုဋေ
၇၂.၄၀ ကုဋေ
၂၆.၂၇ ကုဋေ
၂၄.၀၆ ကုဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၉.၁၉ ကုဋေ
၁၂.၈၃ ကုဋေ
၁၀.၉၀ ကုဋေ
၁၀.၇၆ ကုဋေ
Operating expense
၉.၂၆ ကုဋေ
၁၂.၉၀ ကုဋေ
၁၀.၉၆ ကုဋေ
၁၀.၈၃ ကုဋေ
Total operating expenses
၄၆.၂၂ ကုဋေ
၈၅.၃၀ ကုဋေ
၃၇.၂၄ ကုဋေ
၃၄.၉၀ ကုဋေ
Operating income
-၆.၂၉ ကုဋေ
-၄၁.၀၁ ကုဋေ
၃၅.၈၄ ကုဋေ
၅.၂၃ ကုဋေ
Other non operating income
-၇.၀၂ သိန်း
-၃.၃၈ သိန်း
၁.၁၆ သန်း
-၂.၄၆ သိန်း
EBT including unusual items
-၁၉.၄၀ ကုဋေ
-၂၇.၈၃ ကုဋေ
၃၄.၃၂ ကုဋေ
-၁.၇၅ သန်း
EBT excluding unusual items
-၆.၃၉ ကုဋေ
-၄၂.၃၂ ကုဋေ
၃၄.၄၂ ကုဋေ
၃.၆၇ ကုဋေ
Income tax expense
-၁.၄၁ ကုဋေ
၄.၅၅ သန်း
၁.၂၂ ကုဋေ
၃.၁၄ သန်း
Effective tax rate
၇.၂၇%
-၁.၆၄%
၃.၅၆%
-၁၇၉.၅၉%
Other operating expenses
-
-
-
-
Net income
-၁၇.၉၉ ကုဋေ
-၂၈.၂၈ ကုဋေ
၃၃.၁၀ ကုဋေ
-၄.၈၉ သန်း
Net profit margin
-၄၅.၀၆%
-၆၃.၈၆%
၄၅.၂၉%
-၁.၂၂%
Earnings per share
-၀.၁၃
-၃.၅၈
၃.၁၆
၀.၆၄
Interest and investment income
၇.၂၅ သန်း
၈.၀၇ သန်း
၆.၃၆ သန်း
၆.၂၁ သန်း
Interest expense
-၇.၅၆ သန်း
-၂.၀၈ ကုဋေ
-၂.၁၇ ကုဋေ
-၂.၁၅ ကုဋေ
Net interest expenses
-၃.၁၆ သိန်း
-၁.၂၈ ကုဋေ
-၁.၅၄ ကုဋေ
-၁.၅၃ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
-၄.၄၄ ကုဋေ
-၄၀.၄၈ ကုဋေ
၃၆.၉၀ ကုဋေ
၆.၂၇ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ